复方环丙孕酮联合盐酸二甲双胍和马来酸罗格列酮治疗多囊卵巢综合征的疗效比较

目的探讨并比较复方环丙孕酮联合盐酸二甲双胍和复方环丙孕酮联合马来酸罗格列酮治疗多囊卵巢综合征的临床疗效。方法选取我院2009年3月至2012年7月治疗的150例多囊卵巢综合征患者,随机分为A组和B组,每组75例。A组给予复方环丙孕酮联合盐酸二甲双胍治疗,B组给予复方患病孕酮联合马来酸罗格列酮治疗,治疗3个月后同时给予克罗米芬进行促排卵治疗,疗程结束后观察比较两组用药前后黄体生成素（LH）、LH/卵泡刺激素（FSH）、睾酮（T）、胰岛素抵抗（IR）、体重指数（BMI）以及促排卵治疗后的排卵率。结果 T、LH、LH/FSH、IR以及双侧卵巢的卵泡数均比用药前明显降低（P〈0.05）,组间差异无统计学意义;B组患者的T、IR改善情况明显优于A组（P〈0.05）;A组治疗后体重指数明显下降,有统计学意义（P〈0.05）,且显著优于B组（P〈0.05）;促排卵治疗后A、B两组的排卵率分别为84.0%,78.7%,明显高与用药前（P〈0.05）,组间比较差异无统计学意义。结论两种治疗方法在临床中治疗多囊卵巢综合征均取得了良好的治疗效果,且两组用药各有其优势,临床用药时需根据患者症状、体征合理运用,以取得更好的治疗效果。

Comparison efficacy of Compound cyproterone metformin hydrochloride and rosiglitazone maleate Rogge treating polycystic ovary syndrome

Objective To evaluate and compare the United Malays of compound cyproterone mefformin hydrochloride and compound eyproterone acid rosiglitazone treatment of polycystic ovary syndrome clinical effi- cacy. Methods 150 cases were treated in our hospital from March 2009 to July 2012 in patients with polyeystic ovary syndrome, were randomly divided into group A and group B, 75 eases in each group. A group was given compound cyproterone mefformin hydrochloride therapy, group B given compound sick progesterone while giving the United maleate rosiglitazone treatment, after three months of treatment with clomiphene ovulation induction treatment, after treatment, observation and comparison the two groups before and after administration of luteini- zing hormone （ LH）, LH / follicle-stimulating hormone （ FSH）, testosterone （ T）, insulin resistance （ IR）, body mass index （BMI） and ovulation induction ovulation rate. Results T, LH, LH / FSH, IR, and bilateral ovarian follicle number than before treatment significantly reduced （ P 〈 O. 05 ）, no statistical significance be- tween the two groups ; B group of patients with T IR improve the situation significantly superior induced ovula- tion in group A （ P 〈 0. 05 ） ; to treatment A BMI decreased statistically significant （ P 〈 0. 05 ）, and significant- ly better than group B （P 〈0.05） ; A, B groups ovulation rates were 84. 0% , 78. 7%, significantly higher be- fore treatment （ P 〈 0.05 ） between the two groups was not statistically significant. Conclusion The two treat- ment methods in the clinical treatment of polycystie ovary syndrome have achieved a good therapeutic effect, and two sets of medication each with its advantages, clinical medicine based on the patient＇s symptoms, signs ration- al use in order to obtain better treatment effect.